Search Results 1581-1590 of 17013 for First%2Baid

  1. A Study of Nab-Paclitaxel as Maintenance Treatment After Cisplatin-Based Chemotherapy and Surgery for Patients with High-Risk Bladder Cancer - Mayo Clinic

    There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent ...

  2. Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma - Mayo Clinic

    There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent ...

  3. A Study to Evaluate the Safety and Effectiveness of DCR-PHXC to Treat Patients with Primary Hyperoxaluria Type 1 or 2 and Severe Renal Impairment - Mayo Clinic

    There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent ...

  4. TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery - Mayo Clinic

    There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent ...

  5. Study Of GI-102 And PD-1 In Glioblastoma - Mayo Clinic

    ... first dose of study drug. Pre-treatment testing. The following laboratory values obtained ≤15 days prior to registration: Hemoglobin ≥9.0 g/dL. Absolute ...

  6. Mouth cancer - Doctors and departments - Mayo Clinic

    Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to ...

  7. Mouth cancer - Doctors and departments - Mayo Clinic

    Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to ...

  8. Mouth cancer - Doctors and departments - Mayo Clinic

    Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to ...

  9. Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma - Mayo Clinic

    Any venous or arterial thromboembolic event within ≤ 6 months prior to the first dose of study intervention. - Active infection including TB, HIV ...

  10. Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma - Mayo Clinic

    Systemic antineoplastic therapy within 5 half-lives on the first dose of study treatment. Failure to recover from any clinically significant toxicity ...